1
|
Guaitoli V, Alvarez-Ginarte YM, Montero-Cabrera LA, Bencomo-Martínez A, Badel YP, Giorgetti A, Suku E. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma. J Mol Model 2020; 26:222. [PMID: 32748063 DOI: 10.1007/s00894-020-04470-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
We followed a comprehensive computational strategy to understand and eventually predict the structure-activity relationship of thirty-three 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma. The quantitative structure-activity relationship model showed that the inhibitory potency is correlated with the molar volume, a steric descriptor and the net charge calculated value on atom C1 (q1) and N4 (q4) of the pharmacophore, all of them appearing to give a positive contribution to the inhibitory activity. According to experimental and calculated values, the most potent compound would be 3-[4-(azetidin-2-ylmethyl) cyclohexyl]-1-[3-(benzyloxy) phenyl] imidazo [1,5-α]pyrazin-8-amine (compound 23). Docking was used to guess important residues involved in the ATP-competitive inhibitory activity. It was validated by 200 ns of molecular dynamics (MD) simulation using improved linear interaction energy (LIE) method. MD of previously preferred structures by docking shows that the most potent ligand could establish hydrogen bonds with the ATP-binding site of the receptor, and the Ser979 and Ser1059 residues contribute favourably to the binding stability of compound 23. MD simulation also gave arguments about the chemical structure of the compound 23 being able to fit in the ATP-binding pocket, expecting to remain stable into it during the entire simulation and allowing us to hint the significant contribution expected to be given by electrostatic and hydrophobic interactions to the ligand-receptor complex stability. This computational combined strategy here described could represent a useful and effective prime approach to guide the identification of tyrosine kinase inhibitors as new lead compounds.
Collapse
Affiliation(s)
- Valentina Guaitoli
- Laboratory of Theoretical and Computational Chemistry, Faculty of Chemistry, Universidad de La Habana, 10400, La Habana, Cuba
| | - Yoanna María Alvarez-Ginarte
- Laboratory of Theoretical and Computational Chemistry, Faculty of Chemistry, Universidad de La Habana, 10400, La Habana, Cuba
| | - Luis Alberto Montero-Cabrera
- Laboratory of Theoretical and Computational Chemistry, Faculty of Chemistry, Universidad de La Habana, 10400, La Habana, Cuba. .,Department of Chemistry, Johns Hopkins University, Baltimore, MD, USA.
| | | | - Yoana Pérez Badel
- Laboratory of Theoretical and Computational Chemistry, Faculty of Chemistry, Universidad de La Habana, 10400, La Habana, Cuba
| | - Alejandro Giorgetti
- Department Biotechnology, University of Verona, Strada Le Grazie 15, I-37134, Verona, Italy.,IAS-5/INM-9: Computational Biomedicine - Institute for Advanced Simulation (IAS) / Institute of Neuroscience and Medicine (INM), Forschungszentrum Jülich, 52425, Julich, Germany
| | - Eda Suku
- Department Biotechnology, University of Verona, Strada Le Grazie 15, I-37134, Verona, Italy
| |
Collapse
|
2
|
Xi JJ, He RY, Zhang JK, Cai ZB, Zhuang RX, Zhao YM, Shao YD, Pan XW, Shi TT, Dong ZJ, Liu SR, Kong LM. Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents. Arch Pharm (Weinheim) 2019; 352:e1900024. [PMID: 31338897 DOI: 10.1002/ardp.201900024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 04/24/2019] [Accepted: 04/26/2019] [Indexed: 12/19/2022]
Abstract
A series of novel 3-(thiophen-2-ylthio)pyridine derivatives as insulin-like growth factor 1 receptor (IGF-1R) inhibitors was designed and synthesized. IGF-1R kinase inhibitory activities and cytotoxicities against HepG2 and WSU-DLCL2 cell lines were tested. For all of these compounds, potent cancer cell proliferation inhibitory activities were observed, but not through the inhibition of IGR-1R. Selected compounds were further screened against various kinases. Typical compound 22 (50% inhibitory concentration [IC50 ] values, HepG2: 2.98 ± 1.11 μM and WSU-DLCL2: 4.34 ± 0.84 μM) exhibited good inhibitory activities against fibroblast growth factor receptor-2 (FGFR2), FGFR3, epidermal growth factor receptor, Janus kinase, and RON (receptor originated from Nantes), with IC50 values ranging from 2.14 to 12.20 μM. Additionally, the cell-cycle analysis showed that compound 22 could arrest HepG2 cells in the G1/G0 phase. Taken together, all the experiments confirmed that the compounds in this series were multitarget anticancer agents worth further optimizing.
Collapse
Affiliation(s)
- Jian-Jun Xi
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Ruo-Yu He
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Jian-Kang Zhang
- School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang Province, China
| | - Zhao-Bin Cai
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Rang-Xiao Zhuang
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Yan-Mei Zhao
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Yi-Dan Shao
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Xu-Wang Pan
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Ting-Ting Shi
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Zuo-Jun Dong
- College of Pharmacy, Zhejiang University of Technology, Hangzhou, Zhejiang Province, China
| | - Shou-Rong Liu
- Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China
| | - Li-Min Kong
- Department of Pharmacy, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang Province, China
| |
Collapse
|
3
|
Aware V, Gaikwad N, Chavan S, Manohar S, Bose J, Khanna S, B-Rao C, Dixit N, Singh KS, Damre A, Sharma R, Patil S, Roychowdhury A. Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor. Eur J Med Chem 2015; 92:246-56. [DOI: 10.1016/j.ejmech.2014.12.053] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Revised: 12/28/2014] [Accepted: 12/29/2014] [Indexed: 01/20/2023]
|
4
|
Vidadala RSR, Ojo KK, Johnson SM, Zhang Z, Leonard SE, Mitra A, Choi R, Reid MC, Keyloun KR, Fox AMW, Kennedy M, Silver-Brace T, Hume JCC, Kappe S, Verlinde CLMJ, Fan E, Merritt EA, Van Voorhis WC, Maly DJ. Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. Eur J Med Chem 2014; 74:562-73. [PMID: 24531197 DOI: 10.1016/j.ejmech.2013.12.048] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2013] [Revised: 12/23/2013] [Accepted: 12/26/2013] [Indexed: 12/16/2022]
Abstract
Malaria remains a major health concern for a large percentage of the world's population. While great strides have been made in reducing mortality due to malaria, new strategies and therapies are still needed. Therapies that are capable of blocking the transmission of Plasmodium parasites are particularly attractive, but only primaquine accomplishes this, and toxicity issues hamper its widespread use. In this study, we describe a series of pyrazolopyrimidine- and imidazopyrazine-based compounds that are potent inhibitors of PfCDPK4, which is a calcium-activated Plasmodium protein kinase that is essential for exflagellation of male gametocytes. Thus, PfCDPK4 is essential for the sexual development of Plasmodium parasites and their ability to infect mosquitoes. We demonstrate that two structural features in the ATP-binding site of PfCDPK4 can be exploited in order to obtain potent and selective inhibitors of this enzyme. Furthermore, we demonstrate that pyrazolopyrimidine-based inhibitors that are potent inhibitors of the in vitro activity of PfCDPK4 are also able to block Plasmodium falciparum exflagellation with no observable toxicity to human cells. This medicinal chemistry effort serves as a valuable starting point in the development of safe, transmission-blocking agents for the control of malaria.
Collapse
Affiliation(s)
| | - Kayode K Ojo
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Steven M Johnson
- Department of Chemistry, University of Washington, Seattle, WA 98195-1700, USA
| | - Zhongsheng Zhang
- Department of Biochemistry, University of Washington, Seattle, WA, USA
| | - Stephen E Leonard
- Department of Chemistry, University of Washington, Seattle, WA 98195-1700, USA
| | - Arinjay Mitra
- Department of Chemistry, University of Washington, Seattle, WA 98195-1700, USA
| | - Ryan Choi
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Molly C Reid
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Katelyn R Keyloun
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Anna M W Fox
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Mark Kennedy
- Seattle Biomedical Research Institute, Seattle, WA, USA
| | | | - Jen C C Hume
- Seattle Biomedical Research Institute, Seattle, WA, USA
| | - Stefan Kappe
- Seattle Biomedical Research Institute, Seattle, WA, USA; Departments of Global Health, University of Washington, Seattle, WA, USA
| | | | - Erkang Fan
- Department of Biochemistry, University of Washington, Seattle, WA, USA
| | - Ethan A Merritt
- Department of Biochemistry, University of Washington, Seattle, WA, USA
| | - Wesley C Van Voorhis
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Departments of Global Health, University of Washington, Seattle, WA, USA; Departments of Microbiology, University of Washington, Seattle, WA, USA.
| | - Dustin J Maly
- Department of Chemistry, University of Washington, Seattle, WA 98195-1700, USA.
| |
Collapse
|
5
|
Eftekhari-Sis B, Zirak M, Akbari A. Arylglyoxals in Synthesis of Heterocyclic Compounds. Chem Rev 2013; 113:2958-3043. [DOI: 10.1021/cr300176g] [Citation(s) in RCA: 228] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Bagher Eftekhari-Sis
- Department of Chemistry, Faculty
of Science, University of Maragheh, Golshahr,
P.O. Box. 55181-83111, Maragheh, Iran
| | - Maryam Zirak
- Department of Chemistry, Payame Noor University, P.O. Box 19395-3697, Tehran,
Iran
| | - Ali Akbari
- Department of Chemistry, Faculty
of Science, University of Maragheh, Golshahr,
P.O. Box. 55181-83111, Maragheh, Iran
| |
Collapse
|
6
|
Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular database. Int J Mol Sci 2012; 13:17185-209. [PMID: 23242155 PMCID: PMC3546745 DOI: 10.3390/ijms131217185] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Revised: 11/21/2012] [Accepted: 12/11/2012] [Indexed: 11/17/2022] Open
Abstract
Insulin-like growth factor 1 receptor (IGF1R) is an attractive drug target for cancer therapy and research on IGF1R inhibitors has had success in clinical trials. A particular challenge in the development of specific IGF1R inhibitors is interference from insulin receptor (IR), which has a nearly identical sequence. A few potent inhibitors that are selective for IGF1R have been discovered experimentally with the aid of computational methods. However, studies on the rapid identification of IGF1R-selective inhibitors using virtual screening and confidence-level inspections of ligands that show different interactions with IGF1R and IR in docking analysis are rare. In this study, we established virtual screening and binding-mode prediction workflows based on benchmark results of IGF1R and several kinase receptors with IGF1R-like structures. We used comprehensive analysis of the known complexes of IGF1R and IR with their binding ligands to screen specific IGF1R inhibitors. Using these workflows, 17 of 139,735 compounds in the NCI (National Cancer Institute) database were identified as potential specific inhibitors of IGF1R. Calculations of the potential of mean force (PMF) with GROMACS were further conducted for three of the identified compounds to assess their binding affinity differences towards IGF1R and IR.
Collapse
|
7
|
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2011; 1:1153-71. [PMID: 21425998 DOI: 10.4155/fmc.09.89] [Citation(s) in RCA: 219] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The IGF-1 receptor (IGF-1R) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has become a major focus for the development of anticancer agents. RESULTS Our lead optimization efforts that blended structure-based design and empirical medicinal chemistry led to the discovery of OSI-906, a novel small-molecule dual IGF-1R/insulin receptor (IR) kinase inhibitor. OSI-906 potently and selectively inhibits autophosphorylation of both human IGF-1R and IR, displays in vitro antiproliferative effects in a variety of tumor cell lines and shows robust in vivo anti-tumor efficacy in an IGF-1R-driven xenograft model when administered orally once daily. CONCLUSION OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-1R/IR kinase inhibitor with favorable preclinical drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clinical testing.
Collapse
|
8
|
Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW. Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2. Bioorg Med Chem Lett 2011; 21:2092-7. [DOI: 10.1016/j.bmcl.2011.01.139] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Revised: 01/27/2011] [Accepted: 01/31/2011] [Indexed: 10/18/2022]
|
9
|
Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K. Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. Bioorg Med Chem Lett 2011; 21:1342-6. [PMID: 21300544 DOI: 10.1016/j.bmcl.2011.01.047] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2010] [Revised: 01/10/2011] [Accepted: 01/12/2011] [Indexed: 11/24/2022]
Abstract
A series of two classes of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates were synthesized using click chemistry approach. All compounds were evaluated for inhibition of Src kinase and human ovarian adenocarcinoma (SK-Ov-3), breast carcinoma (MDA-MB-361), and colon adenocarcinoma (HT-29). Hexyl triazolyl-substituted 3-phenylpyrazolopyrimidine exhibited inhibition of Src kinase with an IC(50) value of 5.6 μM. 4-Methoxyphenyl triazolyl-substituted 3-phenylpyrazolopyrimidine inhibited the cell proliferation of HT-29 and SK-Ov-3 by 73% and 58%, respectively, at a concentration of 50 μM.
Collapse
Affiliation(s)
- Anil Kumar
- Department of Chemistry, Birla Institute of Technology and Science, Pilani, Rajasthan, India
| | | | | | | | | | | |
Collapse
|
10
|
Werner DS, Dong H, Kadalbajoo M, Laufer RS, Tavares-Greco PA, Volk BR, Mulvihill MJ, Crew AP. Synthetic approaches to 5,7-disubstituted imidazo[5,1-f][1,2,4]triazin-4-amines. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.05.083] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 2010; 52:4981-5004. [PMID: 19610618 DOI: 10.1021/jm9002395] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Rongshi Li
- Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA.
| | | | | |
Collapse
|
12
|
Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62:199-236. [PMID: 20392809 DOI: 10.1124/pr.109.002469] [Citation(s) in RCA: 185] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
This topically limited review explores the relationship between the immune system and insulin-like growth factors (IGF-I and IGF-II) and the proteins through which they act, including IGF-I receptor (IGF-IR) and the IGF-I binding proteins. The IGF/IGF-IR pathway plays important and diverse roles in tissue development and function. It regulates cell cycle progression, apoptosis, and the translation of proteins. Many of the consequences ascribed to IGF-IR activation result from its association with several accessory proteins that are either identical or closely related to those involved in insulin receptor signaling. Relatively recent awareness that IGF-I and IGF-IR regulate immune function has cast this pathway in an unexpected light; it may represent an important switch governing the quality and amplitude of immune responses. IGF-I/IGF-IR signaling may also participate in the pathogenesis of autoimmune diseases, although its relationship with these processes seems complex and relatively unexplored. On the one hand, IGF-I seems to protect experimental animals from developing insulin-deficient diabetes mellitus. In contrast, activating antibodies directed at IGF-IR have been detected in patients with Graves' disease, where the receptor is overexpressed by multiple cell types. The frequency of IGF-IR+ B and T cells is substantially increased in patients with that disease. Potential involvement of IGF-I and IGF-IR in the pathogenesis of autoimmune diseases suggests that this pathway might constitute an attractive therapeutic target. IGF-IR has been targeted in efforts directed toward drug development for cancer, employing both small-molecule and monoclonal antibody approaches. These have been generally well-tolerated. Recognizing the broader role of IGF-IR in regulating both normal and pathological immune responses may offer important opportunities for therapeutic intervention in several allied diseases that have proven particularly difficult to treat.
Collapse
Affiliation(s)
- Terry J Smith
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan Medical School, 1000 Wall Street, Ann Arbor, MI 48105, USA.
| |
Collapse
|
13
|
Sharma S, Kundu B. Application of the Modified Pictet−Spengler Cyclization Reaction for the Preparation of an Imidazopyrazine Ring: Synthesis of new Pyrido- and Pyrimido-imidazopyrazines. ACTA ACUST UNITED AC 2009; 11:720-31. [PMID: 19435370 DOI: 10.1021/cc9000345] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Sunil Sharma
- Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226001, India
| | - Bijoy Kundu
- Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226001, India
| |
Collapse
|
14
|
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg Med Chem Lett 2009; 19:3136-40. [PMID: 19394223 DOI: 10.1016/j.bmcl.2008.12.110] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2008] [Revised: 12/22/2008] [Accepted: 12/30/2008] [Indexed: 11/21/2022]
Abstract
Exploration of the SAR around a series of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines led to the discovery of novel pyrrolopyridine inhibitors of the IGF-1R tyrosine kinase. Several compounds demonstrated nanomolar potency in enzyme and cellular mechanistic assays.
Collapse
|
15
|
Chapter 14 Recent Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2009. [DOI: 10.1016/s0065-7743(09)04414-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
16
|
Chamberlain SD, Redman AM, Patnaik S, Brickhouse K, Chew YC, Deanda F, Gerding R, Lei H, Moorthy G, Patrick M, Stevens KL, Wilson JW, Brad Shotwell J. Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett 2008; 19:373-7. [PMID: 19081716 DOI: 10.1016/j.bmcl.2008.11.065] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2008] [Revised: 11/18/2008] [Accepted: 11/19/2008] [Indexed: 11/25/2022]
Abstract
Initial evaluation of a series 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines revealed a C(1') carboxamide was preferred for sub-micromolar in vitro potency against IGF-1R. Subsequent solution stability studies with 1 revealed a susceptibility toward acid-induced intramolecular cyclization with the C(1') carboxamide. Herein, we describe several successful approaches toward generating both potent and acid-stable inhibitors of IGF-1R within the 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine template.
Collapse
Affiliation(s)
- Stanley D Chamberlain
- GlaxoSmithKline, Oncology R&D, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg Med Chem Lett 2008; 19:469-73. [PMID: 19056263 DOI: 10.1016/j.bmcl.2008.11.046] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2008] [Revised: 11/08/2008] [Accepted: 11/12/2008] [Indexed: 11/23/2022]
Abstract
The evaluation of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines as inhibitors of the IGF-1R (IGF-IR) receptor tyrosine kinase is reported. Examples demonstrate nanomolar potencies in in vitro enzyme and mechanistic cellular assays as well as promising in vivo pharmacokinetics in rat.
Collapse
|
18
|
Velaparthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hurlburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmermann K, Trainor G, Vyas D. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem 2008; 51:5897-900. [PMID: 18763755 DOI: 10.1021/jm800832q] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PXR transactivation, poor aqueous solubility, and high plasma protein binding. Herein we disclose the evolution of this chemotype to address these issues. This effort led to 10 (BMS-695735), which exhibits improved ADME properties, a low risk for drug-drug interactions, and in vivo efficacy in multiple xenograft models.
Collapse
Affiliation(s)
- Upender Velaparthi
- Discovery Chemistry, Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Co., Wallingford, Connecticut 06492, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Receptor guided 3D-QSAR: a useful approach for designing of IGF-1R inhibitors. J Biomed Biotechnol 2008; 2008:837653. [PMID: 18385815 PMCID: PMC2276912 DOI: 10.1155/2008/837653] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2007] [Accepted: 12/17/2007] [Indexed: 01/03/2023] Open
Abstract
Research by other investigators has established that insulin-like growth factor‐1 receptor (IGF-1R) is a key oncological target, and that derivatives of 1, 3-disubstituted-imidazo[1,5-α] pyrazine are potent IGF-1R inhibitors. In this paper, we report on our three-dimensional quantitative structure activity relationship (3D-QSAR) studies for this series of compounds. We validated the 3D-QSAR models by the comparison of two major alignment schemes, namely, ligand-based (LB) and receptor-guided (RG) alignment schemes. The latter scheme yielded better 3D-QSAR models for both comparative molecular field analysis (CoMFA) (q2 = 0.35, r2 = 0.95) and comparative molecular similarity indices analysis (CoMSIA) (q2 = 0.51, r2 = 0.86). We submit that this might arise from the more accurate inhibitor alignment that results from using the structural information of the active site. We conclude that the receptor-guided 3D-QSAR may be helpful to design more potent IGF-1R inhibitors, as well as to understand their binding affinity with the receptor.
Collapse
|
20
|
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924. Bioorg Med Chem Lett 2008; 18:1702-7. [DOI: 10.1016/j.bmcl.2008.01.049] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2007] [Revised: 01/11/2008] [Accepted: 01/14/2008] [Indexed: 12/21/2022]
|
21
|
Shrout AL, Esposito EA, Weis RM. Template-directed assembly of signaling proteins: a novel drug screening and research tool. Chem Biol Drug Des 2008; 71:278-81. [PMID: 18221311 DOI: 10.1111/j.1747-0285.2008.00627.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A multitude of proteins reside at or near the cell membrane, which provides a unique environment for organizing and promoting assemblies of proteins that are involved in a variety of cellular signaling functions. Many of these proteins and pathways are implicated in disease. For example, strong links have been established between receptor tyrosine kinases and disease, most notably, cancer. However, a significant impediment to researchers remains: membrane-associated proteins are difficult to reconstitute and study. Template-directed assembly represents a powerful new technology that enables the assembly of membrane-associated proteins. We show that template-directed assembly restores tyrosine kinase activity and regulation, and provides a way for researchers to build multicomponent assemblies. As an example of better enzyme regulation, the Tie2 tyrosine kinase domain exhibits (biologically relevant) autoinhibitory behavior when template assembled. Also, template-assembled insulin receptor tyrosine kinase domains exhibit significant autophosphorylation (none detected without template-directed assembly) and an eightfold increase in substrate phosphorylation (compared to best solution conditions). Thus, template-directed assembly has a demonstrated ability to effectively produce more biologically relevant results using these commercial reagents. Template-directed assembly promises to be generally applicable to the signaling networks important for human health, because these pathways frequently contain membrane-associated proteins that require the organizing influence of a membrane surface.
Collapse
Affiliation(s)
- Anthony L Shrout
- Protein Attachment Technologies, LLC, 101 University Dr, Suite A5, Amherst, MA 01002, USA.
| | | | | |
Collapse
|
22
|
Velaparthi U, Liu P, Balasubramanian B, Carboni J, Attar R, Gottardis M, Li A, Greer A, Zoeckler M, Wittman MD, Vyas D. Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile. Bioorg Med Chem Lett 2007; 17:3072-6. [PMID: 17398093 DOI: 10.1016/j.bmcl.2007.03.048] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2007] [Revised: 03/13/2007] [Accepted: 03/14/2007] [Indexed: 11/30/2022]
Abstract
A series of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) were examined in which the pendant imidazole moiety was replaced to improve selectivity for IGF-1R inhibition over cytochrome P450 (CYP). Synthesis and SAR of these compounds is presented.
Collapse
Affiliation(s)
- Upender Velaparthi
- Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|